Company / R&D Expense
TEVA PHARMACEUTICAL INDUSTRIES LTD R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$1.0B
FY2025
5-year range
$98.0M / $1.0B
FY2021-FY2025
Trend
+1.5%
vs FY2024
Sector context
#17 of 210
Health Care
What the data says
Among 210 Health Care companies, TEVA PHARMACEUTICAL INDUSTRIES LTD is in the top 8% for r&d expense. R&D Expense has increased for 3 consecutive years, from $98M in FY2022 to $1.0B in FY2025.
Based on SEC 10-K filings.
$1.0B in FY2025 with a 5-year CAGR of +0.3%. Top quartile in the Health Care sector.
Improved from $953M to $1.0B over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +117.8%
- 5-Year CAGR
- +0.3%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 210This company $1.0B Sector average $644.0M
▼
+57.3% above sector average
Key checks
Key Insights
- TEVA PHARMACEUTICAL INDUSTRIES LTD's r&d expense has grown for 3 consecutive years.
- 5-year CAGR of +0.3%, indicating consistent growth.
- In FY2025, r&d expense increased 1.5% year-over-year.
- Ranks #17 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -9.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.0B | +1.5% |
| FY2024 | $998.0M | +4.7% |
| FY2023 | $953.0M | +872.4% |
| FY2022 | $98.0M | -89.9% |
| FY2021 | $967.0M | -3.0% |
| FY2020 | $997.0M | -1.3% |
| FY2019 | $1.0B | +786.0% |
| FY2018 | $114.0M | -34.9% |
| FY2017 | $175.0M | -58.5% |
| FY2016 | $422.0M | +1105.7% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026